- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05612347
Kolonoskopia a badanie kału u starszych polipów jelita grubego (COOP)
Kolonoskopia a badanie kału u starszych osób dorosłych z historią polipów jelita grubego
This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal polyps who are due for surveillance colonoscopy.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Colon polyps are common among adults ≥50 years and people with colon polyps are recommended to undergo regular follow-up colonoscopy (surveillance) in hopes of preventing subsequent colorectal cancer (CRC). Older adults, particularly those who are age ≥70 years, most of whom have a history of only small colon polyps, may benefit little from repeated colonoscopies because of the increased risks of colonoscopy due to age and co-morbidities and potentially limited life expectancy due to other competing medical problems - CRC may never be a problem for them. Older adults may also be hesitant to get repeated colonoscopy because of the risk of complications (e.g., bleeding, perforation, etc.) and inconvenience. More surveillance options are needed to help address the concerns and challenges with repeated colonoscopies in older adults with a history of low-risk polyps.
FIT is a noninvasive, stool-based test that is recommended and widely used in the US and globally for CRC screening in average-risk adults 45 to 75 years of age. In addition, FIT is already standard of care as a surveillance option for patients with a history of low-risk adenomas in Canada and has been shown to be equivalent to colonoscopy for screening of certain high-risk populations (e.g., those with a family history of CRC). However, FIT's role for surveillance among older adults who have a history of low-risk adenomas has not been studied in the US nor among older adults who may benefit from this noninvasive surveillance approach.
The COOP Trial will fill this evidence gap and shed light on patient-, clinician-, and system-factors relevant to FIT for surveillance that together could potentially transform surveillance guidelines in the US and beyond
The purpose of this study is to compare annual at-home stool-based testing, with a fecal immunochemical test (FIT), to colonoscopy in adults age 65-82 who have a history of colorectal polyps. The goal of the study is to compare how well FIT works compared to colonoscopy in looking for and finding colorectal cancer in older adults who have a history of colorectal polyps, as well as to understand people's experiences with using it compared to colonoscopy.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Barbie Patel, MPH
- Numer telefonu: 857-4987233
- E-mail: coopstudy@hitchcock.org
Lokalizacje studiów
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 5A1
- Rekrutacyjny
- University of Calgary
-
Kontakt:
- Dr. Robert Hilsden, MD
- Numer telefonu: 403-592-5042
- E-mail: rhilsden@ucalgary.ca
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6Z 1Y6
- Rekrutacyjny
- University of British Columbia
-
Kontakt:
- Dr. Jennifer Telford, MD
- Numer telefonu: 6046886332
- E-mail: jtelford29@gmail.com
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3EOW3
- Rekrutacyjny
- University of Manitoba
-
Kontakt:
- Harminder Singh, MD
- Numer telefonu: 2047893369
- E-mail: mycolonoscopy@umanitoba.ca
-
-
Ontario
-
London, Ontario, Kanada, N6A 5W9
- Rekrutacyjny
- London Health Sciences Centre Research Institute
-
Kontakt:
- Dr. Michael Sey, MD
- Numer telefonu: 519 685 8500
- E-mail: michael.sey@lhsc.on.ca
-
-
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35233
- Aktywny, nie rekrutujący
- University of Alabama Birmingham
-
-
Arizona
-
Tucson, Arizona, Stany Zjednoczone, 85719
- Rekrutacyjny
- University of Arizona
-
Kontakt:
- Joshua Melson, MD
- Numer telefonu: 5206266119
- E-mail: Cats-med@arizona.edu
-
-
California
-
San Diego, California, Stany Zjednoczone, 92161
- Rekrutacyjny
- Jennifer Moreno Department of Veterans Affairs Medical Cneter
-
Kontakt:
- Dr. Samir Gupta
-
Walnut Creek, California, Stany Zjednoczone, 94596
- Rekrutacyjny
- Kaiser Permanente Northern California
-
Kontakt:
- Jeffrey Lee, MD, MPH
- E-mail: cooptrial@kp.org
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- Rekrutacyjny
- University of Colorado
-
Kontakt:
- Swati Patel, MD, MS
- E-mail: GI-CancerPreventionProgram@cuanschutz.edu
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20010
- Rekrutacyjny
- MedStar Health
-
Główny śledczy:
- Jennifer Tran, MD
-
Kontakt:
- Theresa Moriarty
- Numer telefonu: 2028773657
- E-mail: Theresa.M.Moriarty@medstart.net
-
-
Florida
-
Tampa, Florida, Stany Zjednoczone, 33612-4745
- Rekrutacyjny
- James A. Haley Veterans Hospital
-
Kontakt:
- Brijesh Patel, MD
- Numer telefonu: (813) 619-5131
- E-mail: Kamryn.woods@va.gov
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Rekrutacyjny
- Northwestern Memorial Hospital
-
Główny śledczy:
- Rajesh Keswani, MD
-
Kontakt:
- Zack Jacobs
- Numer telefonu: 3124729597
- E-mail: IGIresearch@northwestern.edu
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46202
- Rekrutacyjny
- Richard L. Roudebush VA Medical Center
-
Kontakt:
- Thomas Imperiale, MD
- Numer telefonu: 317-988-4859
- E-mail: VHAINDVACOOPINDY@va.gov
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48105
- Rekrutacyjny
- University of Michigan Health
-
Kontakt:
- Nabrah Lone
- Numer telefonu: 7346473635
- E-mail: nabrahl@med.umich.edu
-
Główny śledczy:
- Stacy Menees, MD
-
Detroit, Michigan, Stany Zjednoczone, 48202
- Rekrutacyjny
- Henry Ford
-
Kontakt:
- Dr. Suraj Suresh, MD
- Numer telefonu: 313-932-5502
- E-mail: SSuresh1@hfhs.org
-
-
Missouri
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Rekrutacyjny
- Washington University School of Medicine
-
Kontakt:
- Dr. Cassandra Fritz, MD
- Numer telefonu: (314) 374-8335
- E-mail: cfritz@wustl.edu
-
-
New Hampshire
-
Lebanon, New Hampshire, Stany Zjednoczone, 03756
- Rekrutacyjny
- Dartmouth Health
-
Kontakt:
- Audrey Calderwood, MD, MS
- Numer telefonu: (603) 650-0220
- E-mail: coopstudy@hitchcock.org
-
-
New York
-
New York, New York, Stany Zjednoczone, 10010
- Rekrutacyjny
- New York Harbor Health Care System - Dept of Veterans Affairs
-
Kontakt:
- Aasma Shaukat, MD
- E-mail: Aasma.Shaukat@nyulangone.org
-
-
North Carolina
-
Charlotte, North Carolina, Stany Zjednoczone, 28204
- Rekrutacyjny
- Wake Forest University Health Sciences
-
Kontakt:
- Dr. Lee Sigmon, MD
- Numer telefonu: 704-355-2000
- E-mail: Lee.Sigmon@advocatehealth.org
-
-
Oregon
-
Portand, Oregon, Stany Zjednoczone, 97232
- Zakończony
- Kaiser Permanente Northwest
-
Portland, Oregon, Stany Zjednoczone, 97239
- Rekrutacyjny
- Oregon Health & Science University (Knight Cancer Institute)
-
Kontakt:
- Seth Crockett, MD, MPH
- Numer telefonu: (503)494-2278
- E-mail: gastrohepresearch@ohsu.edu
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84112
- Rekrutacyjny
- University of Utah
-
Kontakt:
- Andrew Gawron, MD
- Numer telefonu: 801-581-7802
- E-mail: andrew.gawron@hsc.utah.edu
-
Kontakt:
- Lynette Holman
-
Sandy City, Utah, Stany Zjednoczone, 84094
- Rekrutacyjny
- Intermountain Health
-
Kontakt:
- Dr. Christine Hachem, MD, FACG
- Numer telefonu: 8015072112
- E-mail: Christine.Hachem@imail.org
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22903
- Rekrutacyjny
- University of Virginia Health
-
Kontakt:
- Cynthia Yoshida, MD
- Numer telefonu: 434-243-2124
- E-mail: CoopStudy@virginia.edu
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- English or Spanish speaking
- Personal history of colorectal polyps
- Most recent colonoscopy with ≤2 non-advanced polyps
- Currently due or coming due within 12 months for colonoscopy
- Able to provide written informed consent
Exclusion Criteria:
- Personal history of colorectal cancer
- Personal history of genetic syndrome with high risk for colorectal cancer (e.g. Lynch Syndrome, Familial Adenomatous Polyposis Syndrome (FAP), or Serrated Polyposis Syndrome)
- Personal history of inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease)
- Most recent colonoscopy with advanced polyp(s) or ≥3 non-advanced polyps
- Patients unlikely to benefit from polyp surveillance (e.g., history of heart disease or coronary artery disease with treatment in the last 6 months, heart failure affecting function, lung disease requiring use of home oxygen, stroke within the last 4 months, dementia affecting activities of daily living (ADL) or instrumental activities of daily living (IADL), severe liver disease requiring the use of certain medications to control fluid, confusion, or bleeding, severe kidney disease requiring dialysis, or a new cancer diagnosis within the last year)
- Patients unable to provide written informed consent
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: FIT
FIT (annual) |
Annual FIT |
|
Aktywny komparator: Colonoscopy
Surveillance colonoscopy (one time) |
One time surveillance colonoscopy |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence of advanced neoplasia in each study group, annual FIT and colonoscopy, assessed by comparing the detection of advanced neoplasia between the two study groups.
Ramy czasowe: Up to 11 years
|
The investigators will determine the incidence of advanced neoplasia, defined as adenocarcinoma of the colon or rectum or adenomas or serrated polyps ≥1 cm in size or with villous features or any dysplasia, or traditional serrated polyps, in both study groups through annual surveys asking about any changes in polyp history or new cancer diagnosis for up to 6 years and medical record review for up to 11 years. The incidence of advanced neoplasia will be compared between the two study group cumulatively after all the data has been collected. |
Up to 11 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change from baseline Satisfaction and Trust of colorectal screening testing assessed by Tiro et al (2005) Response Efficacy sub-scale from the general colorectal cancer screening survey.
Ramy czasowe: Baseline, 1 year after surveillance colonoscopy, annually after each completed FIT for up to 6 years
|
The Response Efficacy sub-scale from the general colorectal cancer screening survey is a 2 item scale with five response options (1=strongly disagree, 2=mildly disagree, 3=don't know, 4=mildly agree, 5=strongly agree), such that each individual attains a score ranging from 2 to 10. |
Baseline, 1 year after surveillance colonoscopy, annually after each completed FIT for up to 6 years
|
|
Change from baseline worry about colorectal Cancer assessed by the Cancer Worry Scale (CWS)
Ramy czasowe: Baseline and annually for up to 6 years
|
The Cancer Worry Scale is a six-item scale designed to measure worry about the risk of developing cancer and the impact of worry on daily functioning. The scale consists of six questions with four response options (1 = not at all or rarely; 2 = sometimes; 3 = often; 4 = almost all the time), such that each individual attains a score ranging from 6 (minimum worry) to 24 (maximum worry). |
Baseline and annually for up to 6 years
|
|
Change from baseline Perceived colorectal cancer susceptibility using Absolute perceived susceptibility to colorectal polyps subscale from McQueen (2010)
Ramy czasowe: Baseline, annually for up to 6 years
|
The absolute perceived susceptibility to colorectal polyps subscale from McQueen (2010) is a three-question scale using four-point Likert format ranging from 1= strongly disagree to 4=strongly agree, such that each individual attains a score ranging from 3 (minimum susceptibility) to 12 (maximum susceptibility). |
Baseline, annually for up to 6 years
|
|
Change from baseline Emotional benefit of surveillance assessed by a modified version of the Psychological Consequences Questionnaire (PCQ)
Ramy czasowe: Baseline and annually for up to 6 years
|
The PCQ is a 22 question scale that has four response options (1=Not at all, 2=a little bit, 3=quite a bit, 4=a great deal) such that each individual attains a score ranging from 22 to 88. |
Baseline and annually for up to 6 years
|
|
Change from baseline perceived global health assessed by the Patient-Reported Outcomes Measurement Information System-Global 10
Ramy czasowe: Baseline and annually for up to 6 years
|
The Patient-Reported Outcomes Measurement Information System-10 is a 10-item scale that has five response options (5=excellent, 4=very good, 3=good, 2=fair, 1=poor) which assess overall QOL. Raw scores are transformed into T scores; higher T scores indicate greater endorsement of the construct being assessed. Scoring supports two summary scores: A Global Physical Health (GPH) score and a Global Mental Health (GMH) score. |
Baseline and annually for up to 6 years
|
|
Major and minor harms within 30 days of colonoscopy, as measured through chart review and telephone interview.
Ramy czasowe: 30-45 days post colonoscopy for up to 6 years
|
Major and minor harms within 30 days of colonoscopy will be collected through chart review and a telephone interview with participants 30-45 post study surveillance colonoscopy or study colonoscopy for positive FIT. The incidence of harms will be compared between the study groups (annual FIT and colonoscopy). |
30-45 days post colonoscopy for up to 6 years
|
Współpracownicy i badacze
Współpracownicy
Śledczy
- Główny śledczy: Audrey H Calderwood, MD, MS, Dartmouth-Hitchcock Medical Center
- Główny śledczy: Theodore R Levin, MD, Kaiser Permante Northern California
Publikacje i pomocne linki
Publikacje ogólne
- Kothari ST, Huang RJ, Shaukat A, Agrawal D, Buxbaum JL, Abbas Fehmi SM, Fishman DS, Gurudu SR, Khashab MA, Jamil LH, Jue TL, Law JK, Lee JK, Naveed M, Qumseya BJ, Sawhney MS, Thosani N, Yang J, DeWitt JM, Wani S; ASGE Standards of Practice Committee Chair. ASGE review of adverse events in colonoscopy. Gastrointest Endosc. 2019 Dec;90(6):863-876.e33. doi: 10.1016/j.gie.2019.07.033. Epub 2019 Sep 25.
- Gupta S, Lieberman D, Anderson JC, Burke CA, Dominitz JA, Kaltenbach T, Robertson DJ, Shaukat A, Syngal S, Rex DK. Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2020 Mar;158(4):1131-1153.e5. doi: 10.1053/j.gastro.2019.10.026. Epub 2020 Feb 7. No abstract available.
- Dubé C, McCurdy BR, Bronstein T, et al. ColonCancerCheck Recommendations for Post-Polypectomy Surveillance, 2019. Available at: https://www.cancercareontario.ca/en/content/coloncancercheck-recommendations-post-polypectomy-surveillance
- Quintero E, Carrillo M, Gimeno-Garcia AZ, Hernandez-Guerra M, Nicolas-Perez D, Alonso-Abreu I, Diez-Fuentes ML, Abraira V. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening. Gastroenterology. 2014 Nov;147(5):1021-30.e1; quiz e16-7. doi: 10.1053/j.gastro.2014.08.004. Epub 2014 Aug 13.
- Warren JL, Klabunde CN, Mariotto AB, Meekins A, Topor M, Brown ML, Ransohoff DF. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009 Jun 16;150(12):849-57, W152. doi: 10.7326/0003-4819-150-12-200906160-00008.
- May S, Knight EM, Boyer N, Calderwood AH, Biddle KM, Marks AR, Badalov JM, Jensen CD, Levin TR, Robertson DJ, Cronholm PF, Kearney MD, Barg FK, Jones L, Edwards WD, O'Shea E, Geddes J, Schifferdecker KE. Mixed-Methods Development and Validation of PRO/PREM Items for Patients Undergoing Colon Polyp Surveillance. J Clin Gastroenterol. 2026 Apr 27. doi: 10.1097/MCG.0000000000002386. Online ahead of print.
- Robertson DJ, Dominitz JA, Beed A, Boardman K, Del Curto BJ, Guarino PD, Huang GD, Imperiale TF, LaCasse A, Larson M, Gupta S, Lieberman D, Planeta B, O'Leary TJ, Shaukat A, Sultan S, Kyriakides TC; CONFIRM Study Group. Race, ethnicity, and prior colorectal screening test use in CONFIRM colonoscopy vs fecal immunochemical testing trial participants. JNCI Cancer Spectr. 2026 Aug 26:pkag080. doi: 10.1093/jncics/pkag080. Online ahead of print.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Nowotwory według lokalizacji
- Nowotwory
- Choroby jelit
- Nowotwory przewodu pokarmowego
- Nowotwory Układu Pokarmowego
- Choroby przewodu pokarmowego
- Nowotwory jelit
- Choroby odbytu
- Choroby okrężnicy
- Choroby Układu Pokarmowego
- Nowotwory jelita grubego
- Techniki i procedury diagnostyczne
- Diagnoza
- Procedury chirurgiczne, operacyjny
- Minimalnie inwazyjne procedury chirurgiczne
- Techniki diagnostyczne, chirurgiczne
- Endoskopia, przewód pokarmowy
- Endoskopia, układ trawienny
- Techniki diagnostyczne, układ trawienny
- Endoskopia
- Procedury chirurgiczne układu trawiennego
- Kolonoskopia
Inne numery identyfikacyjne badania
- STUDY02001984
- PLACER-2020C3-20955 (Inny numer grantu/finansowania: Patient-Centered Outcomes Research Institute (PCORI))
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .